In a recent Science paper, Herbert et al. 1 provided compelling data supporting the association of the single nucleotide polymorphism (SNP) rs7566605 with body mass index (BMI) and obesity. rs7566605 was identified in an initial genome-wide association screen and subsequently replicated in five of six samples (meta-analytic odds ratio with obesity 1.22, 95% CI 1.05-1.42, P = 0.008 under a recessive model). 1 Using baseline and longitudinal data from the CATIE randomized clinical trial of schizophrenia, 2 we first investigated whether rs7566605 was associated with BMI and second, given the paucity of genotyping in the region of this SNP in the original report, whether other SNPs in the same haplotype block were associated.
We genotyped rs7566605 (chr2:118,552,255) plus 10 additional SNPs in 756 participants in CATIE, a double-blinded randomized clinical trial of typical and atypical antipsychotics under controlled conditions with follow-up for as long as 18 months, and in which all subjects provided informed consent under IRB approval. 2 Briefly, inclusion criteria required a definite diagnosis of schizophrenia, age 18-65 years, clinical decision that oral medication was appropriate, adequate decisional capacity and provision of written informed consent. Exclusion criteria essentially stipulated that participation was safe and clinically reasonable.
3 BMI was measured serially across the trial. 3 Haplotype tagging SNPs were selected (by applying TAGGER 4 to the HapMap2 genotypes for CEU and YRI samples) and genotyped using TaqMan 5 blind to all phenotypic data. All SNPs passed quality control (48 duplicate samples/SNP agreed with originals, overall no-call rate was 0.53%, and all SNPs were in Hardy-Weinberg equilibrium). Analyses were conducted using multiple regression in SAS 6 The association results are summarized in the Table  1 and full results are in the Supplemental Table. First, we did not replicate the association of rs7566605 with baseline BMI or for BMI change across all CATIE Phase 1/1A treatments under recessive and general association models. We observed a non-significant statistical trend similar in magnitude to that reported by Herbert et al.
1 for a recessive model at rs7566605 (in subjects of European ancestry, mean BMI (s.d.) was 31.9 (0.94) for the CC genotype versus 30.8 (0.43) for combined CG/GG genotypes). There were insufficient numbers to investigate drug-specific associations with treatment across Phase 1/1A.
Second, rs7566605 lies in an apparently intergenic B31.7 kb haplotype block; as Herbert et al.
1 conducted limited genotyping in this region, we genotyped 10 additional tSNPs (ranging from chr2:118,525,681-118,559,164) in the vicinity of rs7566605 (chr2:118,552,255). As shown in the Supplemental Table, there were no significant associations of these SNPs with BMI at CATIE baseline or longitudinally across CATIE Phase 1/1A. Third, we conducted haplotype analyses 7 for four-SNP sliding windows across the genotyped region. In the Europe only and Africa only ancestral strata, global P-values for all haplotype comparisons were greater than 0.10 for baseline BMI. Fourth, we repeated the above analyses with waist:hip ratio and also found no significant associations.
In conclusion, we were unable to replicate the reported association of rs7566605 with BMI.
1 Explanations for our negative findings include the possibility that the initial report was false and that statistical power was insufficient. Alternatively, the nature of obesity may be different in individuals with schizophrenia than in more typical samples like those studied by Herbert et Catechol-O-methyltransferase (COMT) was first described by Axelrod et al.,
1 who later partially purified and characterized this important enzyme. 2 COMT is responsible for the O-methylation of catecholamines resulting in modulation and increase in dopamine levels in the prefrontal cortex. [3] [4] [5] Recent reports consider COMT as an important gene; which may be involved in cognition, modulation of prefrontal cortex and genetic predisposition towards schizophrenia. 5 There is one single gene for COMT, which codes for both soluble and membrane-bound isoforms of COMT. 3 Genetic polymorphisms have also been described associating COMT activity with several other neuropsychiatric conditions such as obsessivecompulsive disorder, antisocial behavior, late-onset alcoholism and rapid cycling bipolar disorder. 3 Brain COMT is present in neurons, 6 glial 7 and ependymal cells. 6 The soluble COMT is localized to the cytosol and nucleus whereas the membrane-bound COMT is present in the endoplasmic reticulum. 3 Male COMT knockout mice lack COMT activity and exhibit a threefold increase in dopamine levels in the frontal cortex. 8 Subjects with velocardiofacial syndrome, who have a COMT deletion at chromosome 22q11, exhibit a higher incidence of schizophrenia. 5 Recent experiments performed in our laboratory evaluated the effects of chronic administration of several psychotropic agents such as clozapine (20 mg/kg/day), fluoxetine (10 mg/kg/day), haloperidol (1.5 mg/kg/day), lithium chloride (50 mg/kg/day), olanzapine (2 mg/kg/day), sodium valproate (300 mg/ kg/day) versus saline, on brain gene regulation, in male Sprague-Dawley albino rats. Animals were randomly assigned to one of the six drug groups or sterile saline and administered drugs or diluent intraperitoneally for 21 days. The University of Minnesota Animal Care Committee approved all experimental procedures. Animals were killed, brains were removed and frontal cortices were dissected and flash-frozen in liquid nitrogen and stored at À801C for future assays. The tissues were then homogenized and analyzed for DNA and protein levels using DNA microarray technique or sodium dodecyl sulfatepolyacryl amide gel electrophoresis and Western blotting, respectively, following previous procedures.
9,10 Differences for all protein levels for COMT were normalized against b-actin and assayed using a Student's t-test. Significant differences are defined as those with a P-value < 0.05.
Microarray results showed a significant (P < 0.05), twofold decrease in mRNA for COMT in all drug treatment groups (except for olanzapine) when compared with controls ( Table 1 ). The soluble COMT (24 kDa band) was significantly downregulated in the frontal cortex by clozapine (P = 0.014), lithium (P = 0.0006), olanzapine (P = 0.046) and sodium valproate (P = 0.0073; Figure 1) ; was significantly upregulated by fluoxetine (P = 0.0063); and unaffected by haloperidol (Table 1 ). In contrast, the membranebound COMT (28 kDa band) was downregulated significantly (P = 0.0073) by sodium valproate only ( Figure 1 and Table 1 ).
There were no statistically significant differences in the levels of b-actin in any of the drug-treated brains
